[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier St Anne\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":683},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,45,0,25,[9,43,70,95,120,144,164,201,235,262,298,328,355,383,409,433,464,493,515,541,561,583,605,629,648],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100522694","transcranial-ultrasonic-stimulation-in-treatment-resistant-depression--an-open-label-pilot-trial-100522694",false,"NCT06085950","Transcranial Ultrasonic Stimulation in Treatment-resistant Depression : an Open-label Pilot Trial","Transcranial Ultrasonic Stimulation in Treatment-resistant Depression: an Open-label Pilot Trial","StimulUS","Inclusion Criteria:\n\n* Age between 18 and 75 years,\n* Diagnosis of major depressive episode (MDE) as part of major depressive disorder as defined by DSM-5 criteria\n* Severe MDE (HDRS-17\\> 20)\n* Drug resistance to at least two well-conducted antidepressant treatment lines\n* With stable antidepressant treatment for at least 4 weeks before inclusion\n* Benefiting from a social security scheme\n* Having given their consent to participate\n\nExclusion Criteria:\n\n* Psychiatric history other than a mood disorder\n* Neurological history, including epilepsy and intracerebral calcifications\n* History of substance use disorder other than tobacco\n* Contraindication to brain MRI (pacemaker, neurostimulator, injury from metallic shine, …)\n* Compulsory psychiatric care\n* Protected adults, people under legal safeguard\n* Pregnant or breastfeeding woman\n* Women of childbearing age who do not have a negative pregnancy test and are not using contraception","ALL","18 Years","75 Years",{"count":22,"type":23},32,"ESTIMATED","INTERVENTIONAL",[26],"NA","The primary objective of this study is to optimize the protocol for the TUS administration in patients with TRD while gaining an initial impression of treatment efficacy.",[29],"Treatment Resistant Depression","RECRUITING","2026-06-18",{"date":33,"type":34},"2026-06-22","ACTUAL",{"date":36,"type":34},"2023-05-09",{"date":38,"type":23},"2028-06",{"name":40,"class":41},"Centre Hospitalier St Anne","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":54,"briefSummary":48,"conditions":55,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100641623","efficacy-of-transcranial-direct-current-stimulation-tdcs-in-the-treatment-of-adult-attention-deficithyperactivity-disorder-adhd-100641623","NCT07652788","Efficacy of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention-Deficit\u002FHyperactivity Disorder (ADHD)","Efficacy of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention-Deficit\u002FHyperactivity Disorder (ADHD): A Randomized Double-Blind Controlled Trial","TDACS","Inclusion Criteria:\n\n* Adult patient aged 18 to 60 years inclusive\n* Patient diagnosed with Attention-Deficit\u002FHyperactivity Disorder (ADHD), combined or predominantly inattentive presentation, previously established by a healthcare professional\n* Patients must be registered in the active caseload of the Adult Neurodevelopmental Disorders Unit (STNDA)\n* Stable psychotropic medication regimen for at least four weeks prior to inclusion, in terms of both molecule and dosage, particularly for methylphenidate, or no current psychotropic treatment. Medication must remain unchanged throughout study participation, unless medically justified changes are required\n* Patient with a cognitive status deemed sufficient by the unit's referring psychiatrist to ensure appropriate completion of the scales and tests included in the protocol\n* Free, informed, and written consent\n\nExclusion Criteria:\n\n•General condition impairment (severe fatigue or marked weakness, convalescence after an acute illness or surgery, or recent alcohol consumption)\n\nPsychiatric and neurological disorders\n\n* Diagnosis of Autism Spectrum Disorder (ASD)\n* Diagnosis of personality disorder (Cluster A, B, C, or other), according to DSM-5-TR\n* Diagnosis of schizophrenia spectrum disorder or other psychotic disorders according to DSM-5-TR\n* Diagnosis of bipolar disorder with manic episode or history of manic episodes according to DSM-5-TR\n* Confirmed neurological disorder\n* Epilepsy or history of epileptic seizures\n\nMedical comorbidities\n\n* Patient with known or suspected cardiac disease\n* Patient with severe pulmonary disease\n* Patient with cerebrovascular disease (e.g., stroke)\n\nDermatological and surgical contraindications\n\n* Patient with scalp lesions, open wounds, or skin conditions (severe acne, herpes, burns, skin fissures)\n* Patient with severe dermatitis, oozing eczema, or fragile scalp\n* Patient with major surgical scars\n* Patient with recent craniotomy\n\nImplantable devices and materials\n\n• Patient with a pacemaker or intracranial electrodes, presence of intracranial metal, or skull defects (e.g., post-craniectomy or trepanation without reconstruction)\n\nOther criteria:\n\n* Simultaneous participation in another non-pharmacological intervention provided in the STNDA day hospital (e.g., psychoeducation, cognitive remediation, body expression therapy, emotional regulation training)\n* Patient with non-pathological ASRS screening scores (fewer than 4 of the first 6 items rated \"Very often\")\n* Insufficient proficiency in the French language\n* Patient under legal guardianship, curatorship, or judicial protection\n* Pregnant or breastfeeding patient (based on clinical interview)","60 Years",{"count":53,"type":23},40,[26],[56],"Attention Deficit\u002FHyperactivity Disorder(ADHD)",[58,59,60],"stimulation;","transcranial direct current stimulation (tDCS)","Échelle ASRS","NOT_YET_RECRUITING","2026-06-11",{"date":64,"type":34},"2026-06-17",{"date":66,"type":23},"2026-06-01",{"date":68,"type":23},"2028-02-20",{"name":40,"class":41},{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":42},"100634813","phenotypic-exploration-during-sensory-stimulation-in-an-acoustic-chamber-100634813","NCT07544563","Phenotypic Exploration During Sensory Stimulation in an Acoustic Chamber","Exploration phénotypique en Contexte de Stimulations Sensorielles en Chambre Acoustique","EMO-INTRA","Inclusion Criteria:\n\n* For patients : epilepsy\n* For healthy volunteers: age \\> 18 yo\n\nExclusion Criteria:\n\n* For patients and healthy volonteers : Deafness\n* For healthy volunteers : History of neurological conditions (including stroke, coma, epilepsy, neuro-inflammatory or neurodegenerative disease) or diagnosed cognitive impairment",true,{"count":80,"type":23},320,"OBSERVATIONAL","An observational behavioural and neurophysiological study of the effects of controlled sensory stimulation (such as music, for example) on brain function",[84,85,86],"Epilepsy","Anxiety","Depression Anxiety Disorder","2026-04-15",{"date":89,"type":34},"2026-04-22",{"date":91,"type":34},"2025-12-02",{"date":93,"type":23},"2035-12-02",{"name":40,"class":41},{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":18,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":24,"phases":107,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},"100500449","phase-3-efficiency-of-a-composite-personalised-care-on-functional-outcome-in-early-psychosis-100500449","NCT05796401","Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis","PsyCARE Trial - \"Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis : A Prospective Randomised Controlled Trial \"","PSYCARE","Inclusion Criteria:\n\n* Adolescent and young adults, both sexes, aged 15 to 30 years,\n* Persons characterised according to the CAARMS criteria \\[8\\] as UHR or FEP in the first year after having received diagnosis and care, if any\n* Informed and written signed consent,\n* Participant with regular health insurance\n\nExclusion Criteria:\n\n* Severe and unstabilised medical conditions,\n* Insufficient level in reading and\u002For French language,\n* Current participation in another intervention trial or in a full cognitive remediation programme,\n* Enforced hospitalization ,\n* Intellectual Deficiency (i.e. Intelligence Quotient\\\u003C70), and \u002F or sensorimotor deficits incompatible with the cognitive reinforcement,\n* Former treated episode of psychosis, chronic schizophrenia, schizoaffective, or Bipolar disorder (preceeding the 12 months established in the inclusion criteria),\n* Current severe depression (in case of doubt, MADRS \\> 34),\n* Receiving therapeutic levels of antipsychotics for more than 12 months,\n* Current medication with benzodiazepine \\>30 mg per day equivalent diazepam\n* Current daily use of substance of abuse other than nicotine and alcohol and higher than an average equivalent of 5 cannabis cigarettes AND\u002FOR severe substance use disorder (DSMV criteria\u002Fdependence DSMIV criteria) other than nicotine during the last 6 months or for more than 5 years.\n* Pregnant women, parturients, and lactating women,\n* Individuals deprived of their liberty by a judicial or administrative decision, persons under psychiatric care under articles L3212-1 and 3213-1 (Public Health Code),\n* Individuals of legal age who are the subject of a legal protection measure or unable to express their consent","15 Years","30 Years",{"count":106,"type":23},500,[108],"PHASE3","Chronic psychosis, including schizophrenia is now viewed as a progressive disorder where cognitive deficits predate the clinical onset. Early intervention programs improve the general outcome with staged care strategies, supporting the view that the period before and around the first episode of psychosis is a window of opportunity for improving its functional recovery.\n\nPioneering epigenetic analyses indicate that psychosis onset involves oxidative stress and inflammation suggesting that neuroprotective strategies could limit or even prevent the onset of or the transition into a chronic disorder. Several biological factors associated with the emergence of psychosis can all be rectified by using safe and easily accepted supplements including alterations folate deficiency\u002Fhyperhomocysteinemia; redox imbalance and deficit in polyunsaturated fatty acids (PUFA). The prevalence of these anomalies (20-30%) justifies a systematic detection and could guide personalised add-on strategy.\n\nCognitive remediation improves quality of life (QoL) and functional outcome in patients with chronic psychosis. It would even be more efficacious in the early phase of psychosis by tackling the negative impact of psychosis on education achievement and employment. However, cognitive dysfunctions are often overlooked in patients at ultra-high risk (UHR) for psychosis and patient with a first episode of psychosis (FEP) and cognitive remediation is not always accessible. New technologies can provide us with youth-friendly, non-stigmatising tools, such as applications with cognitive strategies, motivational tools and functioning guidance personalised according to the need of each individual. Patients can have access to it, wherever they live.\n\nEarly psychosis can be associated with inflammation, metabolic deficiency, as well as early structural brain anomalies that reflect brain plasticity abilities and could influence the prognosis and response to cognitive training.\n\nThe study hypothesis is that promoting neuroplasticity by cognitive training and personalised virtual psychoeducation guidance could attenuate or reverse early cognitive deficits and improve the overall functional outcome in young patients UHR or FEP and that this effect is modulated by individual brain plasticity abilities. The overall objective of PsyCARE\\_trial is to improve early intervention in psychosis by providing a composite personalised care (CPC) that will enable personalised cognitive training and psychoeducation guidance, adapted to individuals' needs, cognitive abilities and biological background.",[111],"Psychosis",{"date":113,"type":34},"2026-04-20",{"date":115,"type":34},"2023-12-15",{"date":117,"type":23},"2029-02-15",{"name":40,"class":41},13,{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":24,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":42},"100624605","study-of-the-effectiveness-of-a-systematic-minimal-early-intervention-on-care-engagement-in-adults-with-eating-disorders-requesting-specialized-treatment-100624605","NCT07411807","Study of the Effectiveness of a Systematic Minimal Early Intervention on Care Engagement in Adults With Eating Disorders Requesting Specialized Treatment.","Study of the Effectiveness of a Systematic Minimal Early Intervention on Care Engagement in Adults With Eating Disorders Requesting Specialized Treatment: A Monocentric Pilot Study.","AGIS-TCA","Inclusion Criteria:\n\n* Individual who has submitted a request for care to the CMME for an eating disorder (anorexia nervosa or bulimia)\n* Adult (18 years or older) Resident of the Île-de-France region\n\nExclusion Criteria:\n\n* Body mass index (BMI) greater than 30 kg\u002Fm²: these patients will be directed, from the first telephone contact, to structures or care networks that can offer appropriate treatment.\n\nPoor understanding of the French language\n\nSensory impairment significantly affecting telephone communication\n\nPatient currently receiving care at a specialized eating disorder facility at the time of the call\n\nPatient not consenting to participate in the study\n\nSubject under legal protection measures (guardianship or curatorship)",{"count":129,"type":23},215,[26],"Eating disorders (EDs) are complex psychiatric conditions-such as anorexia nervosa and bulimia nervosa-often emerging in young adulthood and associated with high morbidity and mortality. Despite their severity, access to specialized care remains difficult, delayed by shame, stigma, and a lack of insight among patients, as well as long waiting times and limited specialized resources.\n\nThe AGIS-TCA pilot study aims to evaluate the effectiveness of a systematic minimal early intervention designed to reduce the number of patients lost to follow-up between their request for specialized care and the actual start of treatment.\n\nThis monocentric, low-risk interventional study will be conducted at the Clinique des Maladies Mentales et de l'Encéphale (CMME), GHU Paris Psychiatrie \\& Neurosciences. The intervention includes three early, structured telephone calls and five online support group sessions offered during the waiting period for care.\n\nThe main objective is to determine whether this proactive approach decreases attrition rates (\"lost to follow-up\") compared with a historical cohort. Secondary objectives include assessing the acceptability of early phone contact, adherence to support groups, and describing the clinical and sociodemographic profiles of patients requesting care or lost to follow-up.\n\nThe expected benefit is to facilitate timely access to care for vulnerable patients, prevent symptom worsening, and strengthen engagement in treatment pathways. Risks and constraints are minimal, as participation involves only remote interactions without any invasive procedures.",[133],"Eating Disorders",[135],"Anorexia Nervosa, Bulimia Nervosa","2026-02-09",{"date":138,"type":34},"2026-02-17",{"date":140,"type":34},"2025-12-29",{"date":142,"type":23},"2027-04",{"name":40,"class":41},{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":24,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100623337","impact-of-relaxation-sessions-using-a-virtual-reality-application-on-the-sleep-quality-of-caregivers-working-night-shifts-100623337","NCT07395323","Impact of Relaxation Sessions Using a Virtual Reality Application on the Sleep Quality of Caregivers Working Night Shifts","Impact of Using a Virtual Reality Application on the Sleep Quality of Caregivers Working Night Shifts","Luciole","Inclusion Criteria:\n\n* State-certified nurse or nursing assistant (GHU, GHPG staff)\n* Regularly working night shifts and on duty in the units\n* Age 18 years and over\n* Informed individuals who have signed written consent\n* Individuals affiliated with a social security scheme and must be able to understand and read French.\n\nExclusion Criteria:\n\n* No possibility of follow-up (subjects on fixed-term contracts, ongoing transfers, student reinforcements, etc.)\n* Subjects with insufficient command of the French language, preventing them from taking the tests\n* Pregnant or breastfeeding women (disruption of the sleep cycle), or women with young children.\n* Individuals with a pacemaker or any other implanted medical device, unless medically advised otherwise (due to the radio-magnetic waves emitted by the virtual reality headset)\n* Individuals with epilepsy.",{"count":53,"type":23},[26],"This project aims to evaluate the impact of relaxation sessions conducted using a virtual reality device on the sleep quality of night-shift healthcare workers. The intervention specifically targets the immediate post-night-shift period, a critical time for recovery, by offering immersive guided relaxation experiences designed to reduce anxiety and promote both mental and physiological relaxation.",[156],"Sleep Disorder","2026-02-06",{"date":136,"type":34},{"date":160,"type":23},"2026-02-01",{"date":162,"type":23},"2027-05-01",{"name":40,"class":41},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":51,"enrollmentInfo":171,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":173,"conditions":174,"keywords":178,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100621888","psychometric-validation-of-the-mqol-fr-and-descriptive-assessment-of-quality-of-life-in-patients-with-meningiomas-100621888","NCT07376473","Psychometric Validation of the MQOL-FR and Descriptive Assessment of Quality of Life in Patients With Meningiomas","MenQOL 2","Inclusion Criteria :\n\n* Inclusion Criteria:\n* Age ≥ 18 years\n* Diagnosis of intracranial meningioma on imaging and\u002For confirmed by surgery\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Individuals deprived of liberty by judicial\u002Fadministrative decision or under compulsory psychiatric care\n* Insufficient French language proficiency\u002Fcomprehension\n* Unable to complete the questionnaires independently\n* Unable to express non-opposition to participation",{"count":172,"type":23},238,"This non-interventional study aims to validate the French version of a meningioma-specific quality-of-life questionnaire (MQOL-FR) and to describe health-related quality of life in adults diagnosed with an intracranial meningioma.\n\nParticipants will be invited to complete online questionnaires through a secure REDCap link. After reading the study information and recording their non-opposition, participants will complete: (1) MQOL-FR (meningioma-specific), (2) EQ-5D-5L (generic health-related quality of life), and (3) FACT-Br (brain tumor-specific quality of life). The questionnaire session takes approximately 30-45 minutes and can be completed in more than one sitting using a REDCap access code. There is no additional visit and no change in usual care.\n\nThe study will recruit adults (≥18 years) with a meningioma diagnosis based on imaging and\u002For confirmed by surgery, through the GHU Paris-Sainte-Anne neurosurgery clinic and through patient\u002Fcommunity networks. The goal is to obtain 100 fully completed MQOL-FR questionnaires suitable for psychometric analyses.",[175,176,177],"Intracranial Meningioma","Meningioma","Health-related Quality of Life",[179,180,181,182,183,184,185,186,187,188,189,190,191,192],"meningioma","intracranial meningioma","quality of life","health-related quality of life","HRQoL","patient-reported outcomes","PRO","questionnaire validation","psychometric validation","MQOL","FACT-Br","EQ-5D-5L","REDCap","neurosurgery","2026-01-30",{"date":195,"type":34},"2026-02-03",{"date":197,"type":23},"2026-02-02",{"date":199,"type":23},"2026-09-02",{"name":40,"class":41},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":78,"sex":18,"minAge":19,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":24,"phases":211,"briefSummary":212,"conditions":213,"keywords":219,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":42},"100619139","sensory-mechanisms-of-manual-dexterity-recovery-after-stroke-a-prospective-cohort-study-of-prediction-and-cerebral-correlates-100619139","NCT07340736","Sensory Mechanisms of Manual Dexterity Recovery After Stroke: a Prospective Cohort Study of Prediction and Cerebral Correlates","HapticS 2","Inclusion Criteria:\n\n* First symptomatic stroke, ischaemic or haemorrhagic in the early subacute phase (up to 3 weeks post-stroke)\n* Upper limb paresis (≤4\u002F5 MRC Scale)\n* Ability to grasp, lift and put down 1 block (from the BBT test)\n* Be affiliated to a social security\n\nExclusion Criteria:\n\n* Presence of another neurological or musculoskeletal condition affecting upper limb movement\n* Severe cognitive impairment and\u002For aphasia with inability to understand and carry out instructions\n* Contraindications to MRI (claustrophobia, presence of cochlear implants and\u002For pacemakers)\n* Persons subject to legal protection measures\n* Persons subject to judicial protection measures\n* Pregnancy\n* Life-threatening conditions or conditions requiring follow-up at 6 months\n* Epilepsy\n* Known hypersensitivity or allergy to silicone","85 Years",{"count":210,"type":23},90,[26],"In the proposed research, we will assess motor and sensory functions of the hand using clinical tests and a tool designed to measure manual dexterity combined with vibrotactile stimulation. We will also evaluate the integrity of brain structure and function using MRI.",[214,215,216,217,218],"Stroke","Upper Extremity Paresis","Manual Dexterity","Sensory Integration Dysfunction","Vibration",[220,221,222,223,224,225,226],"stroke","haptic","vibration","sensorimotor impairment","manual dexterity","prediction of recovery","MRI","2026-01-05",{"date":229,"type":34},"2026-01-14",{"date":231,"type":23},"2026-03-01",{"date":233,"type":23},"2028-03-01",{"name":40,"class":41},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":24,"phases":245,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":4},"100615874","anticipating-depressive-and-manic-episodes-in-bipolar-disorders-using-vocal-biomarkers-100615874","NCT07298278","Anticipating Depressive and Manic Episodes in Bipolar Disorders Using Vocal Biomarkers","ANTICIPATING DEPRESSIVE AND MANIC EPISODES IN BIPOLAR DISORDERS USING VOCAL BIOMARKERS","SPEECHBIPO","Inclusion Criteria:\n\n* Adult patient\n* Patient capable of providing informed consent\n* Patient suffering from bipolar disorder according to DSM-5-TR (2022) criteria\n* Patient recently discharged from hospitalization or in remission after a mood episode within the last 12 months, with a MADRS score ≤10 and a YMRS score ≤8, or based on the psychiatrist's subjective evaluation\n* Patient treated with lithium\u002Fantipsychotics\u002Fbenzodiazepines (monotherapy or combination therapy)\n* Patient capable of performing speech assessments and responding to questionnaires on a smartphone\n* Patient able to speak, read, and understand French\n* Patient enrolled in a social security system\n\nExclusion Criteria:\n\n* Patient with a cognitive disorder\n* Patient suffering from a known demential disorder\n* Patient receiving treatment for a known addictive disorder\n* Patient with a condition affecting speech production\n* Patient with a neurological disorder (stroke or neurodegenerative diseases)\n* Patient under legal protection, guardianship, or curatorship\n* Subjects deprived of liberty by judicial or administrative decision\n* Pregnant or breastfeeding women",{"count":244,"type":23},170,[26],"Bipolar disorder (BD) is a chronic, cyclical mental illness affecting over 1% of the global population. It is characterized by alternating episodes of elevated mood and energy (mania or hypomania) and episodes of decreased mood and energy (depression).\n\nManic episodes involve hyperactivity, decreased need for sleep, grandiosity, accelerated speech, and sometimes psychotic symptoms such as hallucinations or delusions. Depressive episodes, in contrast, are characterized by sadness, low energy, social withdrawal, sleep and appetite disturbances, and low self-esteem. Bipolar patients are at very high risk of suicide, with rates up to 20 times higher than in the general population; nearly half will attempt suicide during their lifetime, and 15-20% of these attempts are fatal.\n\nBD is associated with a substantial decrease in quality of life, often greater than that seen in other mood or anxiety disorders. This reduction is primarily driven by depressive symptoms, including residual ones that may persist during remission periods. The frequent comorbidity with anxiety disorders further exacerbates the burden of the illness.\n\nRecently, research has turned toward the concept of the digital phenotype to identify early markers of relapse using passive and continuous monitoring. Among potential digital biomarkers, voice has shown particular promise. Automated speech analysis, combined with machine learning algorithms, has demonstrated effectiveness in detecting psychiatric symptoms and differentiating mood states. In BD, vocal and linguistic patterns vary with mood fluctuations, suggesting that voice could serve as a sensitive indicator of relapse risk.\n\nThe main hypothesis of the present study is that automated analysis of speech and lifestyle data can help develop a predictive model capable of identifying early signs of relapse, whether manic, depressive, or mixed, or transitions to high-risk states in individuals with bipolar disorder.",[248],"Bipolar Disorder (BD)",[250,251,252,253],"Bipolar Disorders","Digital Biomarkers","Speech Analysis","Relapse prediction","2025-12-17",{"date":256,"type":34},"2025-12-23",{"date":258,"type":23},"2025-12-20",{"date":260,"type":23},"2027-05",{"name":40,"class":41},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":78,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":24,"phases":272,"briefSummary":273,"conditions":274,"keywords":278,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":297},"100615672","characterization-of-high-level-cognitive-impairments-in-patients-with-neuropsychiatric-disorders-100615672","NCT07295652","Characterization of High-Level Cognitive Impairments in Patients With Neuropsychiatric Disorders","Characterization of High-level Cognitive Impairments in Patients With Neuropsychiatric Disorders","COGPSY","Inclusion Criteria:\n\nFor patients:\n\n* Aged over 18 years\n* Diagnosed with a psychiatric disorder according to ICD-10 by a psychiatrist (F10-F98) or diagnosed with a neurological disorder according to ICD-10 by a neurologist (G00-G99)\n* Provided written informed consent\n* Affiliated with a social security scheme\n\nFor healthy volunteers:\n\n* Aged over 18 years\n* Provided written informed consent\n* Affiliated with a social security scheme\n\nExclusion Criteria:\n\nFor healthy volunteers:\n\n* Current diagnosis of a psychiatric disorder according to ICD-10 (F20-F98) or current prescription of a psychotropic medication, or diagnosis of a neurological disorder according to ICD-10 (G00-G99)\n* History of depression (F32)\n* Substance use disorder (excluding tobacco)\n* Neurological history (e.g., stroke, coma, epilepsy, neuroinflammatory or neurodegenerative disease) or identified cognitive disorder\n* Inability to complete cognitive testing (e.g., due to motor or sensory impairment)\n\nFor participants undergoing MRI (without contrast agent):\n\n* Presence of MRI contraindications: non-MRI-compatible pacemaker, heart valve, implant, or metallic foreign body\n* Pregnancy at the time of MRI",{"count":271,"type":23},600,[26],"Neuropsychiatric disorders are extremely common, severe, and disabling conditions. In the field of psychiatry, they notably include schizophrenia, mood disorders (depressive and bipolar disorders), autism spectrum or neurodevelopmental disorders, obsessive-compulsive disorder, eating disorders, and personality disorders. In the field of neurology, one can cite neurodegenerative diseases (such as Alzheimer's disease, but also frontotemporal dementia or Parkinson's disease, which often represent frequent and challenging differential diagnoses of psychiatric disorders), focal neurological lesions (notably strokes and tumors), or epilepsy.\n\nCognitive impairments are present in nearly all neuropsychiatric disorders and contribute significantly to disability.\n\nWhile impairments in working memory and attention, executive functions, and social cognition have been relatively well studied, other cognitive domains remain largely unexplored in these populations. This is particularly the case for various aspects of motivation, metacognition, conscious access, or causal (Bayesian) inference.\n\nAlthough these domains likely play an important role in prognosis, no consensus currently exists regarding the methods for evaluating these functions.\n\nThe main objective of this study is to define a multidimensional, transdiagnostic atlas of high-level cognitive impairments-both specific and shared-across severe psychiatric disorders (notably schizophrenia, depressive disorder, bipolar disorder, autism spectrum or neurodevelopmental disorders, and obsessive-compulsive disorder) and neurological disorders (notably neurodegenerative diseases, focal neurological lesions, and epilepsy), by comparing them to healthy volunteers.\n\nThe investigators also aim to investigate the progression of cognitive impairments over time, across different phases of illness (symptom stabilization or exacerbation) or therapeutic intervention, through longitudinal follow-up of patients being monitored within the recruiting center.\n\nFinally, in a more exploratory manner, the investigators aim to investigate the neural correlates of the identified cognitive impairments.",[275,276,248,277],"Neurologic Disorders","Schizophrenia","Depressive Disorder",[279,280,281,282,283,284,285,286,287,288],"Cognitive dysfunction","Executive function","Metacognition","Motivation","Social cognition","Transdiagnostic approach","High-level cognition","Longitudinal cognitive changes","Cognitive profiling","Differential diagnosis","2025-12-16",{"date":291,"type":34},"2025-12-19",{"date":293,"type":34},"2024-03-12",{"date":295,"type":23},"2039-03",{"name":40,"class":41},3,{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":78,"sex":18,"minAge":306,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":24,"phases":310,"briefSummary":311,"conditions":312,"keywords":319,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":4},"100614735","assessment-of-language-comprehension-and-learning-in-children-attending-child-psychiatry-services-ticoala-soins-100614735","NCT07283458","Assessment of Language Comprehension and Learning in Children Attending Child Psychiatry Services (TICOALA-SOINS)","TICOALA-SOINS : Assessment of Language Comprehension and Learning in Children Attending Child Psychiatry Services. Pilot Study of Acceptability and Feasibility.","TICOALA-SOINS","Inclusion Criteria:\n\n* Children (boys or girls) aged 3-7 years\n* Consulting in the child psychiatry service\n* Enrolled in a French-speaking school\n\nExclusion Criteria:\n\n* Inability to use the tablet-based TICOALA tool due to severe sensory (blindness, deafness), motor, or intellectual impairment\n* Refusal of the child or parents\u002Flegal guardians to participate\n* Child not affiliated with the French social security system","3 Years","7 Years",{"count":309,"type":23},50,[26],"Language is central to children's cognitive, emotional, and social development, and language difficulties are a frequent reason for consultation in child psychiatry, often co-occurring with psychiatric disorders. Yet, systematic language assessment is rarely possible due to the limited availability of speech-language therapists in these services.\n\nThe TICOALA tool (Interactive Test of Language Comprehension and Learning on tablet) offers a quick and engaging way to evaluate lexical and syntactic comprehension and word learning. This study aims to assess its acceptability among children aged 3-7 attending a child psychiatry service in Paris, as well as among clinicians and parents. Secondary goals include testing the feasibility of a larger study, describing children's language skills, and examining how these relate to clinical and background variables.",[313,314,315,316,317,318],"Typical Development","Typically Developing Children Ages 3 to 6","Typical Preschoolers Who Can Not Zipper","Children","Children Behavior Problem","FRENCH STUDY",[320],"language assessment","2025-12-15",{"date":291,"type":34},{"date":324,"type":23},"2026-01-03",{"date":326,"type":23},"2028-03-03",{"name":40,"class":41},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":78,"sex":18,"minAge":19,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":24,"phases":338,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":352,"leadSponsor":354,"locationsCount":42},"100611377","role-of-the-noradrenergic-system-in-the-regulation-of-learning-dynamics-evaluation-of-the-effect-of-a-low-dose-selective-noradrenaline-reuptake-inhibitor-noisyxetine-100611377","NCT07239791","Role of the Noradrenergic System in the Regulation of Learning Dynamics: Evaluation of the Effect of a Low-dose Selective Noradrenaline Reuptake Inhibitor (NOISYXETINE)","NOISYXETINE","Inclusion Criteria:\n\n* Right-handed, assessed by the Edinburgh scale;\n* Written signed informed consent;\n* Subject covered by a social security regimen.\n\nExclusion Criteria:\n\n* Pregnant, parturient or breastfeeding woman;\n* First-degree family history of axis I disorder (DSM-IV-TR), excepted unipolar mood and anxiety disorders with OCD;\n* Personal history of axis I disorder (DSM-IV-TR) in the 6 months preceding the study entry;\n* Dependence on a psychoactive substance in the 12 months preceding the study entry, excluding nicotine, any behavioural disorder incompatible with a 2-hour electroencephalographic recording;\n* Neuro\u002Fpsychotropic treatment ongoing or stopped less than 1 month ago;\n* Personal history of neurological pathology (e.g.: congenital malformation, benign or malignant tumour, degenerative disease of the central nervous system (CNS), epilepsy, inflammatory or infectious disease of the CNS, etc.);\n* Personal history of chronic disease of infectious, neoplastic, vascular, dysimmune or inflammatory, metabolic or endocrine, degenerative or genetic aetiology. In particular, angle-closure glaucoma, pheochromocytoma, known high blood pressure or measured blood pressure greater than 140\u002F90 mm Hg at baseline, congenital heart disease, known ischemic heart disease, known heart failure, supraventricular or ventricular heart rhythm disorder, nephropathy, known liver disease and any pathology likely to be aggravated by an increase in blood pressure;\n* Any medical treatment in the month preceding the study entry, apart from effective contraceptive treatment;\n* Subject deprived of liberty by a judicial or administrative decision;\n* Person subject to a legal protection measure or unable to express consent;\n* Known intolerance to atomoxetine;\n* Need to wear glasses and\u002For lenses to obtain normal vision;\n* Subject in an exclusion period or enrolled in an interventional study.","39 Years",{"count":337,"type":23},160,[26],"Administration of low-dose selective noradrenaline reuptake inhibitor (sNRI) (e.g. atomoxetine) to healthy subjects is a validated model of increasing cortical noradrenaline levels which, combined with computational modelling of behaviour, allows fine-grained analysis of the impact on learning processes of noradrenaline's fluctuations in the human cortex.\n\nThe study goal is to characterize the modifications of certain cognitive processes and associated brain circuits under low-dose sNRI using validated computational learning models. The study will be interested in how subjects will modify their learning under the effect of the drug across two separate investigations; one utilizing in a stable evidence accumulation task and one utilising a changing evidence accumulation task. This approach will help to better understand the link between noradrenaline and accumulation of evidence in healthy subjects, and indirectly in some neuropsychiatric pathologies.\n\nThe study is a single centre, double-blinded, randomized, placebo-controlled, cross-over study involving evaluable healthy adults separated in 2 cohorts: A for participants having the stable task and B for those having the changing one. Participants will then be randomized in a 1:1 ratio to one of the following treatment sequences:\n\n* Atomoxetine 40 mg - Placebo (Subgroups A1 or B1);\n* Placebo - Atomoxetine 40 mg (Subgroups A2 or B2).",[341,342],"Role of the Noradrenergic System in the Regulation of Learning Dynamics","No Disease or Condition is Being Studied",[344,345,346,347],"noradrenaline","learning dynamics","atomoxetine","healthy subject","2025-11-18",{"date":350,"type":34},"2025-11-20",{"date":348,"type":34},{"date":353,"type":23},"2027-12",{"name":40,"class":41},{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":24,"phases":364,"briefSummary":366,"conditions":367,"keywords":370,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":42},"100609096","phase-2-efficacy-of-psilocybin-and-trazodone-combination-in-treatment-resistant-depression-a-randomized-controlled-proof-of-concept-study-psilotraz-100609096","NCT07210112","Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)","PSILOTRAZ","Inclusion Criteria:\n\n* Patient with major depressive episode without psychotic features according to DSM-5 criteria;\n* Treatment-resistant depressive episode, i.e. failure to respond to at least two lines of antidepressant medication at an adequate dose and for a sufficient period of time (6 weeks according to the MGH-ATRQ);\n* MADRS ≥ 20;\n* Written signed informed consent;\n* Patient covered by the social security system.\n\nExclusion Criteria:\n\nPsychiatric comorbidities known from medical history or identified during inclusion assessment:\n\n* Bipolar disorder;\n* Schizophrenia and psychosis;\n* Personal or family history of psychotic disorder;\n* History of personality disorder;\n* Post-traumatic stress disorder, obsessive-compulsive disorder, eating disorders;\n* Alcohol or substance use disorder in past 12 months or positive urine toxins at time of assessment;\n* Significant suicide risk, as defined by: (a) suicidal ideation as indicated by items 4 or 5 on the C-SSRS within the past six months, at Screening, during the Screening Period, or at Baseline (b) demonstrating suicidal behaviors in the past six months, or; (c). clinical assessment of significant suicidal risk or risk of self-injury during participant interview;\n* Patient with a psychiatric decompensation following a previous use of psychedelic substance like LSD;\n\nComorbidities or somatic specificities:\n\n* Pregnancy and breastfeeding women;\n* Cardiovascular history (myocardial infarction, stroke, heart rhythm disorder, uncontrolled hypertension, QT interval prolongation, tachycardia and poor cardiovascular health);\n* Uncontrolled diabetes;\n* Uncontrolled thyroid disorder;\n* Epilepsy;\n* Parkinson's disease treated by selegiline or levodopa;\n* HIV treated by ritonavir and indinavir;\n* Active infection treated by erythromycin;\n* Fungal infection treated by ketoconazole and itraconazole;\n* Contraindications to MRI;\n\nConcomitant therapies:\n\n* 5-HT antagonist treatment2A (including quetiapine, olanzapine, aripiprazole);\n* Lithium treatment;\n* Treatment with buprenorphine or opioids, clonidine, methyldopa, digoxin, Monoamine oxidase inhibitors (MAOI), aldehyde dehydrogenase (ALDH) inhibitors and alcohol dehydrogenase (ADH) inhibitors, St. John's Wort, or warfarin should be discontinued completely before study drug administration;\n* Use of electroconvulsive therapy and\u002For transcranial magnetic stimulation, during the current depressive episode; or lifetime vagus nerve stimulation, deep brain stimulation, and\u002For ablative neurosurgery;\n* Use of psychedelics (psilocybin, lysergic acid, ayahuasca, mescaline and derivatives) during current episode;\n\nLegal status:\n\n* Persons deprived of their liberty by judicial or administrative decision, persons under compulsory psychiatric care;\n* Persons under legal protection or unable to give consent;\n\nOther:\n\n\\- Any clinical manifestation which, in the opinion of the investigator, may interfere with the interpretation of study results or constitute a health risk to the participant if he or she participates in the study.",{"count":363,"type":23},112,[365],"PHASE2","Psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects.\n\nThe benefit-risk ratio of psilocybin in treatment-resistant depression seems favorable, but needs to be confirmed. Moreover, the role of 5-HT2A receptors, involved in the psychedelic experience, on the therapeutic efficacy of psilocybin is still poorly understood. For example, pre-administration of trazodone, a 5-HT2A antagonist antidepressant, could annihilate the acute subjective effects of psilocybin without altering its beneficial effects (Rosenblat et al., 2023). We intend to test this hypothesis by comparing, in a randomized, double-blind, placebo-controlled study, the effect of two possible doses of trazodone (total or partial occupancy of 5-HT2A receptors) on the benefit\u002Frisk ratio of psilocybin.\n\nWe hypothesize that the therapeutic effects of psilocybin are partially independent of 5-HT2A receptor activation and thus persist even after total or partial neutralization of its acute subjective effects.",[368,369],"Depression - Major Depressive Disorder","Treatment-resistant Depression (TRD)",[371,372,373,374],"psilocybin","trazodone","TRD","RCT","2025-09-29",{"date":377,"type":34},"2025-10-07",{"date":379,"type":23},"2025-10-08",{"date":381,"type":23},"2030-06-30",{"name":40,"class":41},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":24,"phases":393,"briefSummary":394,"conditions":395,"keywords":396,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":42},"100608499","targeted-intervention-on-sleep-disorders-during-tobacco-or-cannabis-cessation-therapy-100608499","NCT07202351","Targeted Intervention on Sleep Disorders During Tobacco or Cannabis Cessation Therapy","Impact of an Intervention Targeting Sleep Disorders During Tobacco or Cannabis Cessation Therapy: a Randomised Pilot Study","ISAC","Inclusion Criteria:\n\n* patients over 18 years old\n* presenting at the participating addiction treatment centres for a smoking or cabannis use cessation therapy\n* who agree to participate to the study\n* affiliated to the French health insurance system\n\nExclusion Criteria:\n\n* Patients hospitalised during the cessation therapy\n* Patients undergoing sleep disorders treatment\n* Patients participating to another study\n* Patients with psychotic disorders (according the DSM-5 classification)\n* Patients who do not want the additionnal intervention and care if randomised in the intervention group",{"count":392,"type":23},80,[26],"During a cessation therapy for tobacco or cannabis, sleep disorders are one of the main risk factors of relapse, and a symptom of substance withdrawing. In this study, we make the hypothesis that identifying and managing potential sleep disorders during cessation treatment may contribute to maintain tobacco \u002F cannabis abstinence on the long-term. To evaluate the impact of such intervention, we will conduct a randomised pilot study among patients consulting at two addiction prevention and care centres, for smoking or cannabis use cessation treatment. Control group will benefit of usual care (a multidisciplinary care with individual and group therapies); intervention group will benefit in addition of a systematic screening of sleep disorders, and in case of a diagnosed alteration, they will be addressed to the Chronos centre, for specific care to help them manage and reduce the consequences of their sleep disorders. Participants will be followed over a 6-month period, with visits at 1 and 3 months, to monitor smoking or cannabis cessation, and other criteria associated with their substance use or sleep.",[156],[397,398,399,400],"sleep disorder","tobacco","cannabis","addiction","2025-09-23",{"date":403,"type":34},"2025-10-01",{"date":405,"type":34},"2023-06-05",{"date":407,"type":23},"2026-08-31",{"name":40,"class":41},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":24,"phases":417,"briefSummary":418,"conditions":419,"keywords":421,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":42},"100607878","feasibility-and-preliminary-results-of-the-efficacy-of-blue-blocking-glasses-on-manic-symptoms-in-bipolar-disorder-100607878","NCT07194278","Feasibility and Preliminary Results of the Efficacy of Blue-Blocking Glasses on Manic Symptoms in Bipolar Disorder","B2Bi","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patient with a type 1 bipolar disorder presenting a manic episode according to the DSM-5 TR, with or without associated psychotic disorders.\n\nExclusion Criteria:\n\n* Patient who did not agree to participate to the study\n* Patient unable to be informed or understand the course of the study\n* Patient with severe eye problem or with an history of trauma affecting the eyes\n* Pregnant or breastfeeding women\n* Patient in need of urgent care",{"count":7,"type":23},[26],"The goal of this clinical trial is to assess the feasibility of conducting a clinical trial of the use of blue-blocking glasses among patients with a type1 bipolar disorder, experiencing a manic episode. The feasibility criteria include: recruitment rates, participation rates, adherence to the research protocol, the material feasibility of the study. Feasibility criteria will be assessed at the end of the study period.\n\nThe investigators also want to assess patients' acceptability regarding the use of blue-blocking glasses during a manic episode, using self-reported satisfaction criteria. Those criteria will be monitored at the end of participation period for each patient (7 days after inclusion).\n\nIn addition, the study will evaluate the impact of the use of blue-blocking glasses on the severity of manic symptoms, sleeping pattern (quality of sleep, sleep latency, night wake, etc.), global functioning, and on suicidal ideations. Those indicators will be assessed at day 0 (inclusion), day 3 and day 7, using validated questionnaires and actimetry data.\n\nThe study is presented to all patients over 18 years old, with type 1 bipolar disorder, presenting a manic episode, hospitalised in an adult psychiatric ward of Bichat Hospital (GHU Paris).\n\nPatients' participation duration is of 7 days after inclusion.",[420],"Bipolar 1 Disorder",[422,423,424],"bipolar 1 disorder","blue-blocking glasses","manic episode","2025-09-18",{"date":427,"type":34},"2025-09-26",{"date":429,"type":34},"2024-07-19",{"date":431,"type":23},"2026-09-01",{"name":40,"class":41},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":441,"targetDuration":443,"studyType":81,"phases":4,"briefSummary":444,"conditions":445,"keywords":448,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":463},"100605893","transfusion-exchanges-and-cognition-in-sickle-cell-disease-100605893","NCT07168447","Transfusion Exchanges and Cognition in Sickle Cell Disease","Effect of Exchange Transfusions on Cognitive Efficiency in Patients With Sickle Cell Disease","DREPA-COG","Inclusion Criteria:\n\n* Adults (≥18 years) with severe sickle cell disease (SS or Sβ0).\n* Enrolled in a regular monthly transfusion exchange program.\n* Not institutionalized.\n* No known dementia.\n* No severe aphasia.\n* Affiliated with or beneficiary of a social security system.\n\nExclusion criteria:\n\n* Insufficient mastery of spoken French.\n* Severe comorbidities preventing short-term follow-up.\n* Known psychiatric disorders.\n* Participation in another clinical study with ongoing exclusion periods.\n* Lack of adequate computer equipment (minimum 11-inch screen and internet connection).\n* Vulnerable patients under legal protection (guardianship or curatorship).",{"count":442,"type":23},85,"6 Weeks","DREPA-COG is an observational study evaluating the effect of exchange transfusions on cognitive function in adults with severe sickle cell disease (SS or Sβ0). Information processing speed is assessed at three time points during the transfusion cycle using the Symbol Digit Modalities Test (SDMT) and additional validated neuropsychological measures. This minimal-risk, fully remote study aims to identify processing speed as a reproducible marker for clinical monitoring and future therapeutic trials.",[446,447],"Drepanocytosis","Chronic Neurological Deficiency",[449,450,451,452,453,454],"Sickle cell disease","cognitive function","neuropsychological assessment","transfusion exchange","non-interventional study","executive function, SDMT, T-MoCA, fatigue, anxiety, depression","2025-09-04",{"date":457,"type":34},"2025-09-11",{"date":459,"type":23},"2025-12-03",{"date":461,"type":23},"2027-11-02",{"name":40,"class":41},6,{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":24,"phases":474,"briefSummary":475,"conditions":476,"keywords":478,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":490,"leadSponsor":492,"locationsCount":4},"100604087","phase-3-cilostazol-with-nimodipine-to-improve-outcome-after-aneurysmal-subarachnoid-hemorrhage-100604087","NCT07144956","Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage","Is Adding Cilostazol to Nimodipine Improving Neurological Outcome of Patients With Aneurysmal Subarachnoid Hemorrhage? A Randomized, Double Blind, Placebo-controlled Trial","CASH","Inclusion Criteria:\n\n* Adult patients admitted to an ICU with SAH related to a ruptured cerebral aneurysm occurring within the last 96 hours.\n* Aneurysm successfully secured by surgical clipping or endovascular coiling\n* Consent of the patient or, if not possible, from a proxy (emergency clause).\n* Registration in a national health care system\n\nExclusion Criteria:\n\n* \\- Precritical modified Rankin Scale (mRS) \\> 2\n* Nonaneurysmal SAH\n* Delayed \\>96h admission after first symptoms of SAH\n* Coma defined by GCS of 3-5 with untreatable aneurysm will be excluded\"\n* Known allergy to cilostazol\n* Pregnancy\n* Pre-existing major hepatic, renal, pulmonary or cardiac disease\n* Concomitant use of one other anti-platelet and\u002For anticoagulant agent\n* SAH diagnosed on Lumbar puncture with no evidence of blood on CT.\n* Tutelage or guardianship",{"count":473,"type":23},630,[108],"The CASH study is a randomized, double-blind, placebo-controlled trial evaluating whether adding cilostazol to standard nimodipine therapy improves neurological outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). The primary objective is to assess functional outcome at 6 months using the modified Rankin Scale. A total of 630 patients will be enrolled within 96 hours of aSAH onset and treated for 14 days. The study is conducted across 9 centers in France, funded by a PHRC, and overseen by an independent monitoring board.",[477],"Aneurysmal Subarachnoid Hemorrhage",[479,480,481,482,483,484,485,486],"Cilostazol","Nimodipine","Vasospasm","Modified Rankin Scale (mRS)","Neurological outcome","Double-blind","Randomized Controlled Trial","Multicenter clinical trial",{"date":488,"type":34},"2025-09-10",{"date":321,"type":23},{"date":491,"type":23},"2029-12-14",{"name":40,"class":41},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":78,"sex":18,"minAge":500,"maxAge":501,"enrollmentInfo":502,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":504,"conditions":505,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":42},"100582873","implications-of-myelin-in-executive-control-in-adolescence-and-early-adulthood-100582873","NCT06868966","Implications of Myelin in Executive Control in Adolescence and Early Adulthood","MYELEX","Inclusion Criteria:\n\n* Male or female; Subject aged 10 to 25 years; Right-handed preference; Subject, or legal representative, who has given consent to participate; Native language: French; Subject affiliated with a social security system; Having signed their consent to participate (and their legal representative if applicable), subjects and parents have read the information letter and given their free and informed consent. In cases where only one parent gives consent (for minors), this must be justified (such as no contact with the other parent for over a year).\n\nExclusion Criteria:\n\n* Not corresponding to the targeted age range;\n* Subject with contraindications to an MRI examination (pacemaker or neurosensory stimulator or implantable defibrillator, cochlear implants, ferromagnetic foreign bodies in the eyes or brain near neural structures, metal prostheses, patient agitation: non-cooperative or agitated patients, minors, claustrophobic subjects, pregnant women, ventriculoperitoneal neurosurgical shunt valves, dental braces);\n* Subject with chronic alcohol or drug use;\n* Abuse or dependence on substances (except nicotine) or toxic substances for more than 5 years or having led to comas (overdoses);\n* Subject with sudden-onset cognitive disorders that could indicate a stroke; a history of head trauma with loss of consciousness for more than 1 hour, or encephalitis;\n* Subject with chronic neurological, psychiatric, endocrine, hepatic, or infectious conditions;\n* Subject with a history of major illness (diabetes, chronic lung disease, severe cardiac, metabolic, hematological, endocrine, or immunological disorder, cancer);\n* Subject on medication: taking medications likely to interfere with brain imaging measurements (psychotropics, anxiolytic hypnotics, neuroleptics, anti-Parkinsonians, benzodiazepines, steroidal anti-inflammatories, antiepileptics, central analgesics, and muscle relaxants);\n* Color blindness;\n* Inability to comply with the study for geographical or psychiatric reasons;\n* Tattoo incompatible with MRI;\n* Cerebral palsy;\n* Fine motor skills disorder;\n* Pregnant women at the time of inclusion;\n* Adult subjects under legal protection or unable to give consent (article L.1121-8 of the French Public Health Code) (under guardianship or curatorship);\n* Children and parents under legal protection measures","10 Years","25 Years",{"count":503,"type":23},128,"The Myelex study is a fundamental research study that aims to better understand how the brain functions and develops. The objective of this study is to better understand the role of myelin, a sheath that surrounds nerve fibers and determines the speed of information propagation in the brain, in cognitive functioning during development in adolescents and young adults. investigator use Magnetic Resonance Imaging (MRI) because this method allows us to study the anatomy and functioning of the brain in a non-invasive (no injection) and painless manner. investigator focus on cognitive control, a set of cognitive functions in the prefrontal cortex, at the front of the brain, that enable the use of the best strategies on a case-by-case basis to solve problems effectively. These functions are closely associated with academic and professional success and develop late, continuing until early adulthood. The goal of this project is simple: to measure the myelin of nerve fibers using MRI and to evaluate the link with the development of cognitive control. Each participant will undergo an MRI examination and cognitive assessments. The study takes place at the Clinical Research Center of GHU Paris and lasts a total of 3.5 hours, including reception, setup, MRI recording, and the completion of a series of cognitive tasks.",[506],"Mental Health","2025-08-25",{"date":509,"type":34},"2025-09-02",{"date":511,"type":34},"2024-07-12",{"date":513,"type":23},"2028-07",{"name":40,"class":41},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":523,"minAge":19,"maxAge":4,"enrollmentInfo":524,"targetDuration":526,"studyType":81,"phases":4,"briefSummary":527,"conditions":528,"keywords":530,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":4},"100604086","evolution-of-sexual-symptoms-in-paraphilic-sexual-offenders-withwithout-antiandrogen-or-ssri-treatment-100604086","NCT07144943","\"Evolution of Sexual Symptoms in Paraphilic Sexual Offenders With\u002FWithout Antiandrogen or SSRI Treatment\"","Study on the Observation of the Evolution of Sexual Symptoms in Sexual Offenders With Paraphilia (With or Without Antiandrogen or SSRI Treatments)","ESPARA","Inclusion Criteria:\n\n* Men suffering from paraphilias (DSM-5 criteria),\n* Aged 18 to 65 years,\n* Sexual offenders (offense or sexual assault including exhibitionism, rape, sexual touching, incest, possession of pedopornographic video material) (severity level 1 to 6 according to WFSBP recommendations),\n* Subject who has given consent,\n* Patients covered by social security,\n* Satisfactory command of written and spoken French.\"\n\nExclusion Criteria:\n\n* Subject in prison (regardless of the reason),\n* Subject under guardianship (patients under legal supervision may, however, be included),\n* Subjects who have committed a sexual offense and do not meet the DSM-5 criteria for paraphilia.\"","MALE",{"count":525,"type":23},200,"36 Months","The ESPARA study is a multicenter observational research project aiming to monitor, over a three-year period, the evolution of sexual symptoms in male sexual offenders with paraphilia, divided into three groups: receiving antiandrogen treatment, receiving selective serotonin reuptake inhibitors (SSRIs), or no pharmacological treatment. The primary objective is to assess changes in sexual desire intensity and deviant sexual behaviors, while secondary objectives include relapse rates, the role of psychiatric comorbidities, treatment tolerability, and various clinical, cognitive, and life-history factors.",[529],"Sexual Disorder, Physiological",[531,532,521],"sexual offenders","paraphilia","2025-08-20",{"date":535,"type":34},"2025-08-28",{"date":537,"type":23},"2025-09-15",{"date":539,"type":23},"2030-09",{"name":40,"class":41},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":548,"enrollmentInfo":549,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":42},"100603185","neurocognitive-correlates-of-the-influence-of-number-word-syntax-on-magnitude-processing-100603185","NCT07133230","Neurocognitive Correlates of the Influence of Number Word Syntax on Magnitude Processing","NUMWORD","Inclusion Criteria:\n\n* Subject aged 18 to 45 years;\n* Female or male;\n* Right-handed preference;\n* Subject, or legal representative, who has given consent to participate;\n* Native language: French\n* Subject affiliated with a social security system;\n* Having signed their consent to participate (and their legal representative if applicable),\n* Subjects have read the information letter and given their free and informed consent;\n* Normal medical, neurological, and neuroradiological examinations\n* For women of childbearing age, be on effective contraception\n\nExclusion Criteria:\n\n* Not corresponding to the targeted age range;\n* Subject with contraindications to an MRI examination (pacemaker or neurosensory stimulator or implantable defibrillator, cochlear implants, ferromagnetic foreign bodies in the eyes or brain near neural structures, metal prostheses, patient agitation: non-cooperative or agitated patients, minors, claustrophobic subjects, pregnant women, ventriculoperitoneal neurosurgical shunt valves, dental braces);\n* Subject with chronic alcohol or drug use;\n* Abuse or dependence on substances (except nicotine) or toxic substances for more than 5 years or having led to comas (overdoses);\n* Subject with sudden-onset cognitive disorders that could indicate a stroke; a history of head trauma with loss of consciousness for more than 1 hour, or encephalitis;\n* Subject with chronic neurological, psychiatric, endocrine, hepatic, or infectious conditions;\n* Subject with a history of major illness (diabetes, chronic lung disease, severe cardiac, metabolic, hematological, endocrine, or immunological disorder, cancer);\n* Subject on medication: taking medications likely to interfere with brain imaging measurements (psychotropics, anxiolytic hypnotics, neuroleptics, anti-Parkinsonians, benzodiazepines, steroidal anti-inflammatories, antiepileptics, central analgesics, and muscle relaxants);\n* Color blindness;\n* Inability to comply with the study for geographical or psychiatric reasons;\n* Tattoo incompatible with MRI;\n* Cerebral palsy;\n* Fine motor skills disorder;\n* Pregnant women at the time of inclusion;\n* Adult subjects under legal protection or unable to give consent (article L.1121-8 of the French Public Health Code) (under guardianship or curatorship);\n* Children and parents under legal protection measures","45 Years",{"count":550,"type":23},84,"Linguistic irregularities in number naming systems, such as the inversion of number words, affect the processing of Arabic numerals. Recently, it has been claimed that there is even a syntactic representation of number words. participant investigate the neurofunctional correlates of the syntactic processing of number words by examining different levels of place-value processing in a study with two complementary successive phases (Group 1 and Group 2) in healthy adults. In the first phase with Group 1, participant evaluate the unit-decade compatibility effect (UDCE) in two-digit magnitude comparisons. In the second phase with Group 2, participant investigate the carry-over effect in two-digit addition problems.",[553],"Brain Activity","2025-08-19",{"date":533,"type":34},{"date":557,"type":23},"2025-09",{"date":559,"type":23},"2027-10-30",{"name":40,"class":41},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":24,"phases":571,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":42},"100602723","consciousness-prognosis-evaluation-using-olfactory-stimulations-in-comatose-patients-100602723","NCT07127224","Consciousness Prognosis Evaluation Using Olfactory Stimulations in Comatose Patients)","Consciousness Prognosis Evaluation Using Olfactory Stimulations in Comatose Patients","CEOS","Inclusion Criteria:\n\n* Admission to neuro-intensive care unit (neuro-ICU)\n* Age ≥ 18 years\n* Patients with persistent disorders of consciousness defined by an abnormal CRS-R score (\\\u003C16) at 72 hours after sedation withdrawal and spontaneous ventilation\n* Consent obtained from legal representatives or activation of emergency waiver\n* Patient covered by or affiliated with a social security system\n\nExclusion Criteria:\n\n* Pregnancy\n* Brain death\n* Pre-existing ENT or olfactory bulb pathologies that may affect olfactory functions\n* Acute or chronic peripheral neurological diseases that may alter evoked potentials\n* Known neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's disease)\n* Patients under legal guardianship or protective supervision (safeguard or protection measures)",{"count":570,"type":23},96,[26],"The goal of this observational study is to determine whether the clinical response to olfactory stimulation (known as the \"sniff\" response) can help predict 3-month neurological outcomes in ICU patients with persistent disorders of consciousness after sedation withdrawal, regardless of the reason for admission or the initial severity.\n\nThe main questions this study aims to answer are:\n\n* Can the \"sniff\" response to olfactory stimulation predict neurological outcomes at 3 months?\n* Is this response a better prognostic indicator than commonly used neurophysiological tests? Researchers will compare the results obtained from olfactory stimulation with those from somatosensory and auditory stimulations to determine whether the olfactory method provides additional or superior prognostic value.\n\nParticipants will receive additional olfactory stimuli as part of the neurophysiological evaluation for prognostic purposes and be followed up at 3 months for clinical, neurological, and functional evaluation",[574],"Disorders of Consciousness Due to Severe Brain Injury","2025-08-11",{"date":577,"type":34},"2025-08-17",{"date":579,"type":34},"2024-02-05",{"date":581,"type":23},"2027-05-05",{"name":40,"class":41},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":78,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":24,"phases":592,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":602,"leadSponsor":604,"locationsCount":4},"100600667","metabolic-characterization-of-alzheimers-disease-and-frontotemporal-dementia-by-23na-mri-and-fdg-pet-100600667","NCT07100470","Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET","MetaAD_FTD","Inclusion Criteria:\n\n* Patients with Alzheimer's disease\n\n  * CDR (Clinical Dementia Rating Scale) = 0.5 or 1\n  * Progressive amnestic syndrome, associated or not with other cognitive impairments\n  * Biological criteria: CSF biomarkers suggestive of AD-continuum (Jack et al., 2018)\n* Patients with FTD\n\n  * Modifications of the personality and the social conducts in the foreground (behavioral variant) (Rascovsky et al., 2011)\n  * Primary progressive aphasia (Gorno-Tempini et al., 2011):\n\n    * Effortful, agrammatic speech plus at least one of: a) impaired grammar\u002Fsentence comprehension with relatively preserved single word comprehension, or b) groping, distorted speech production (apraxia of speech)\n    * Semantic language disorders\n  * Compatible brain imaging: profile of atrophy and\u002For hypometabolism on FDG-PET (or hypoperfusion on SPECT) compatible with the diagnosis of FTD and\u002For absence of atypia\n  * Biological criteria: No AD profile on CSF biomarkers if available; if CSF not available: diagnosis based on clinical criteria left to the judgment of the investigators\n* Cognitively healthy controls\n\n  * Absence of known psychiatric disorder\n  * Score on the Folstein Mini-Mental State Examination (MMSE \\> or = 27) with no more than one word missing\n  * Normal neuropsychological assessment for the age and the educational level, particularly Scores on the Free and Cued Selective Reminding Test (FCSRT) of \\>25 for free recall and \\>44 for total recall.\n\nExclusion Criteria:\n\n* Subject with an evolving and\u002For badly checked psychiatric pathology (left to the judgment of the investigator).\n* Subject with a grave, severe or unstable pathology (left to the judgment of the investigator) the nature of which can interfere with the variables of evaluation.\n* Epileptic subjects, with poor tolerance to MRI (1.5T, 3T or 7T),\n* Subject presenting contraindications to the MRI such as Pacemaker or stimulating neurosensory or implantable defibrillator, cochlear implants, eye or cerebral ferromagnetic foreign bodies close to nervous structures, metallic prostheses, neurosurgical ventriculoperitoneal shunt valves\n* Known or supposed histories (\\\u003C or = 5 years) of severe alcoholism or misuse of drugs\n* Vascular, inflammatory or expansive, lesion visible on the MRI which can interfere with the criteria of diagnosis.\n* No health insurance\n* Agitation of the patient: not cooperative or agitated patients, claustrophobic subjects",{"count":591,"type":23},55,[26],"Alzheimer's disease (AD) and frontotemporal dementia (FTD) are the most common forms of neurodegenerative dementia. However, their differential and timely diagnosis can be challenging for clinicians, therefore often closing the door for an early and possibly successful treatment before irreversible cerebral damage occurs. Hence, treatment options often become available only at a late point in time. In Alzheimer's disease, early neuroimaging markers are glucose hypometabolism and Amyloid-\u002FTau-depositions (PET). Recent findings from sodium magnetic resonance imaging (23Na-MRI) point to brain tissue sodium concentration as a metabolic marker of AD progression. Sodium is crucial for neurotransmission and cellular homeostasis maintained by the cellular Na+\u002FK+-ATPase, depending on Adenosine-Triphosphate as energy source from the mitochondrial respiratory chain, also interacting with tau and amyloid. In this project, we aim to characterize disease-specific metabolic patterns in AD vs. FTD by performing 23Na-MRI in association to FDG-PET to support early positive and differential diagnosis and therapeutic follow-up in both diseases in association to clinical parameters such as CSF\u002Fblood markers and neuropsychological assessment. Assessment of 7T MRI including 23Na-MRI, 31P-MRS and 1H-MRI is planned with analysis of results in association with FDG-PET, Amyloid- and Tau-PET, blood and CSF biomarkers as well as neuropsychological and clinical assessment.",[595,596,597],"FTD","AD","Healthy Controls","2025-07-28",{"date":600,"type":34},"2025-08-03",{"date":403,"type":23},{"date":603,"type":23},"2029-03-01",{"name":40,"class":41},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":24,"phases":613,"briefSummary":614,"conditions":615,"keywords":616,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":42},"100597097","endarterectomy-versus-stenting-in-patients-with-symptomatic-severe-carotid-stenosis---2-100597097","NCT07054060","Endarterectomy Versus Stenting in Patients With Symptomatic Severe Carotid Stenosis - 2","EVA3S-2","Inclusion Criteria:\n\n* Patient age 18 years or over\n* Hemispheric or retinal transient ischemic attack or a non-disabling stroke (or retinal infarct) within 15 days before enrolment\n* Stenosis of 50% to 99% in the symptomatic carotid artery (NASCET method) for whom revascularisation is decided according to guidelines\n\nExclusion Criteria:\n\n* Patients unwilling or unable to participate in follow-up for whatever reason\n* Preexisting disability (Modified Rankin Score ≥ 3)\n* Nonatherosclerotic carotid disease\n* Severe tandem lesions\n* Previous revascularization of the symptomatic carotid stenosis\n* History of bleeding disorder\n* Unstable angina\n* Contraindication to dual antiplatelet therapy\n* Contraindication to MRI\n* Life expectancy of less than 2 years\n* Percutaneaous or surgical intervention within 30 days before or after the study procedure\n* Stenotic lesion on arterial workup appeared as not a factor in the selection",{"count":271,"type":23},[26],"Carotid stenosis caused by atherosclerosis is a significant risk factor for ischemic stroke, accounting for up to 15% of all strokes and transient ischemic attacks. Randomized clinical trials (RCTs) have demonstrated the benefits of carotid endarterectomy (CEA) in reducing stroke risk in patients with severe symptomatic carotid stenosis. Carotid artery stenting (CAS) has been developed as an alternative to CEA, offering several potential advantages, such as avoiding local surgical complications. However, unlike CEA, CAS has not been compared to medical therapy in RCTs for symptomatic carotid stenosis.",[214],[617,220,618,619,620],"CEA, CAS","Magnetic resonance imaging","Carotid Artery Stenting","Carotid Endarterectomy","2025-07-23",{"date":623,"type":34},"2025-07-24",{"date":625,"type":34},"2025-07-16",{"date":627,"type":23},"2028-03-16",{"name":40,"class":41},{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":633,"acronym":634,"eligibilityCriteria":635,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":636,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":637,"conditions":638,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":42},"100596332","translation-and-validation-of-the-mqol-self-questionnaire-into-french-for-assessing-quality-of-life-in-patients-with-meningiomas-100596332","NCT07044076","Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With Meningiomas","MenQOL","Inclusion Criteria:\n\n* Patient aged 18 years or older\n* Diagnosis of intracranial meningioma confirmed by imaging or surgery\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women (Article L1121-5)\n* Patients deprived of liberty by judicial or administrative decision, as well as individuals undergoing psychiatric care (Article L1121-6)\n* Patients not fluent in French or with poor understanding of the language\n* Inability to refuse participation in the study",{"count":309,"type":23},"Meningiomas, which account for about 40% of primary central nervous system tumors, have significant psychological and social impacts, even without treatment. Their effect on quality of life is often underestimated and poorly documented. There is one validated questionnaire (MQOL) but it has not yet been translated into French. The project involves two phases: first, translating and linguistically validating the MQOL into French; second, scientifically validating the questionnaire with 50 meningioma patients using established scales (EQ-5D, Karnofsky, FACT-Br) to ensure its reliability and internal consistency.",[639,176],"Quality of Life","2025-06-23",{"date":642,"type":34},"2025-06-29",{"date":644,"type":34},"2025-06-13",{"date":646,"type":23},"2025-12-12",{"name":40,"class":41},{"id":649,"slug":650,"hasResults":12,"nctId":651,"briefTitle":652,"officialTitle":653,"acronym":654,"eligibilityCriteria":655,"healthyVolunteers":78,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":656,"targetDuration":4,"studyType":24,"phases":658,"briefSummary":659,"conditions":660,"keywords":665,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":682},"100595551","neuro-computational-study-of-thymic-fluctuations-in-mood-disorders-100595551","NCT07033923","Neuro-computational Study of Thymic Fluctuations in Mood Disorders","Neuro-computational Study of Thymic Fluctuations in Mood Disorders - MOODELING","MOODELING","Inclusion Criteria:\n\nCommon between groups (DD, BD, control and GP):\n\n* Having given informed and written consent\n* Being covered by social security\n\nFor patients with depressive disorder (DD):\n\n* Having been diagnosed with characterized depressive episode (F32, F33, F34) according to the ICD-10, by a psychiatrist, or having presented this diagnosis during the past 12 months\n\nFor patients with bipolar disorder (BD):\n\n* Presenting a diagnosis of bipolar mood disorder (F31) according to ICD-10, by a psychiatrist\n* Having presented a mood episode (F31.0 - F31.6) diagnosed during the past 12 months by a psychiatrist\n\nExclusion Criteria:\n\nCommon between groups (DD, BD, control and GP):\n\n* Inability to carry out daily monitoring on mobile application for 12 months\n* legal protection measure (guardianship or curatorship)\n\nFor control group:\n\n* Current diagnosis of psychiatric disorder in ICD-10 (F20-F98) or prescription of psychotropic treatment\n* History of depression (F32)\n* Syndrome of dependence on a psychoactive substance other than tobacco\n* Neurological history (in particular history of stroke, coma, epilepsy, neuro- inflammatory, or neuro-degenerative disease)\n* Inability to carry out daily monitoring on mobile application for 12 months\n\nFor patients and healthy volunteers for whom an MRI (without injection of contrast agent) is proposed\n\n* Contraindication to MRI: cardiac pacemaker not compatible with MRI, heart valve implant, implant or metallic foreign body\n* Pregnant woman (at the time of MRI)",{"count":657,"type":23},588,[26],"Depression and bipolar disorder are frequent, debilitating conditions. Both are thought to be primarily caused by an impaired regulation of mood, which is why they are sometimes referred to as \"mood disorders\". However, the biological basis of mood remains poorly understood, which is a major limitation for the development of new treatments.\n\nRecent work that combines neuroscience with mathematical models are promising to better understand mood and to link it to its biological basis, but they don't have any medical application yet. Can these models describe mood in a way that is relevant to mood disorders, and help doctors and psychologists predict subsequent clinical evolution? With the objective of extending this framework to real-life fluctuations and to assess its clinical relevance, this study will combine a neuroimaging session with a smartphone-based, longitudinal follow-up. Three groups of 96 subjects each will be recruited: depressive disorder, bipolar disorder and healthy controls. They will have their mood fluctuations assessed first in the lab (in the neuroimaging experiment), then in their daily lives (by providing a few ratings and choices every day on the smartphone app).\n\nThis study will allow to better understand the differences in how patients' mood reacts to daily events, as compared to people who don't suffer from depression or bipolar disorder. The combination of the two steps will allow to assess whether a short neuroimaging evaluation can be useful to predict subsequent clinical evolution during the following months.\n\nThe investigators wanted to add two optional ancillary studies. The first uses a mobile application for implicit, passive, and longitudinal mood assessments through emotion tracking. Indeed, it seems relevant to add this type of evaluation alongside explicit assessments to more accurately detect mood fluctuations.\n\nThe second study uses a mobile application that allows voice recordings. The analysis of these vocal parameters will help to characterize a specific linguistic and vocal profile within the three groups, as well as to identify specific symptoms of conditions such as depression and bipolar disorder.\n\nThese ancillary studies will be offered to both patients and the control group.",[661,662,663,664],"Depression","Bipolar Disorder","Recurrent Depression","Mood Disorders",[666,667,668,669,670,671,672,673,674],"cognitive neuroscience","patient-specific modelling","psychiatry","mood disorders","affective disorders","computational modelling","computational psychiatry","prognosis","predictive medicine",{"date":676,"type":34},"2025-06-24",{"date":678,"type":34},"2024-07-18",{"date":680,"type":23},"2029-07-18",{"name":40,"class":41},2,""]